Synthesis, Structure, and Anti-LSD1 Activity of Novel C-16 Triazole-Fused Isosteviol Derivatives

Key Points

• The study shows enhanced anti-LSD1 activity with novel C-16 triazole-fused isosteviol derivatives, leading to potential therapeutic benefits.
• Key findings indicate a significant improvement in inhibitory results, with some derivatives demonstrating over 75% inhibition.
• Analysis involved the synthesis of various triazole-fused isosteviol compounds, revealing distinct structural advantages for anti-LSD1 activity.
• This work highlights the potential for developing new cancer treatments based on these derivatives; further testing is suggested.